Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

President Trump has announced sweeping tariffs on several countries. Novo Nordisk and Smith & Nephew may be the most at risk ...

The line-up consists of supplements to meet the health needs to patients taking GLP-1 medications for weight loss.

Here's everything you need to know about the new weight loss medication being rolled out by the NHS to treat obesity.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were ... an average weight loss of 20.7% ...

Dividend stocks have been a reliable cornerstone for those who want to anchor their portfolios when markets get shaky. These ...

The 64-year-old former Top Gear host opened up about his weight loss journey following an emergency heart operation last year. Writing in The Times, he admitted trying Ozempic—a drug originally ...